

Joe Lombardo
Governor

Richard Whitley, MS
Director



DEPARTMENT OF HEALTH AND HUMAN SERVICES

DIVISION OF HEALTH CARE FINANCING AND POLICY

Helping people. It's who we are and what we do.



Stacie Weeks,
JD MPH
Administrator

*Si quiere este documento traducido, por favor escriba a dhcftp@dhcftp.nv.gov
如果希望获得本文件的翻译版本, 请提交申请至 dhcftp@dhcftp.nv.gov*

REVISED NOTICE OF PUBLIC MEETING – SILVER STATE SCRIPTS BOARD

AGENDA

Date of Posting: August 31, 2023
Date of Revision: **September 20, 2023**

Date of Meeting: September 28, 2023

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Silver State Script Board.

Place of Meeting: The physical location of this meeting which is open to the public at:

Courtyard by Marriott Las Vegas Convention Center
3275 Paradise Road
Las Vegas, NV, 89109
(702) 791-3600

Please check with staff to verify room location.

Space is limited at the physical location and subject to any applicable social distancing or mask wearing requirements as may be in effect at the time of the meeting for the county in which the physical meeting is held.

Note: If at any time during the meeting an individual who has been named on the agenda or has an item specifically regarding them included on the agenda is unable to participate because of technical or other difficulties, please email rxinfo@dhcftp.nv.gov and note at what time the difficulty started so that matters pertaining specifically to their participation may be continued to a future agenda if needed or otherwise addressed.

Webinar: [Sept SSSB](#)
(See final agenda page for full link or employ the shortened link directly above)
OR
<https://tinyurl.com/26ndjebe>

Audio Only: **+1 (417) 501-2485**

Event Number:

182 610 586#

PLEASE DO NOT PUT THIS NUMBER ON HOLD (*hang up and rejoin if you must take another call*)

YOU MAY BE UNMUTED BY THE HOST WHEN SEEKING PUBLIC COMMENT, PLEASE HANG UP AND REJOIN IF YOU ARE HAVING SIDE CONVERSATIONS DURING THE MEETING

This meeting will be recorded to facilitate note-taking or other uses. By participating you consent to recording of your participation in this meeting.

Closed Executive Session – 1:00 PM

Open Session/Public Meeting – will begin upon completion of the Closed Executive Session

AGENDA

1. Call to Order and Roll Call

2. General Public Comment

*Public comments are encouraged to be submitted in advance so that it may be included in meeting materials and given attention. No action may be taken upon a matter raised through public comment unless the matter itself has been specifically included on an agenda as an action item. Please provide your name in any comment for record keeping purposes. You may submit comments in writing via e-mail to (rxinfo@dncfp.nv.gov). There may be an opportunity to take public comment via telephone or the meeting's virtual platform as well as in person opportunities, but phone participants should disconnect their call and re-join if they must take another call. Do not place your phone on hold or you may disrupt the meeting for other participants. Public comment may be limited to three minutes per person. **Note: this guidance applies for all periods of public comment referenced further in the agenda, such as those related to clinical presentations.***

Public comments may be related to topics on the agenda or matters related to other topics per NRS 241.020(3)(3)(II).

3. Administrative

- a. **For Possible Action:** Review and Approve Updated Meeting Minutes from June 22, 2023.
- b. Status Update by DHCfp.
- c. Status Update by NMAP.

4. Annual Review - Established Drug Classes Being Reviewed Due to the Release of New Drugs (Please note: Drug Classes are in bold below.)

- a. **For Possible Action:** Discussion and possible adoption of **Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and Combinations**
 - i. Public comment.
 - ii. Drug class review presentation by MagellanRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by MagellanRx.

v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

b. **For Possible Action:** Discussion and possible adoption of **Growth Hormone Modifiers**

i. Public comment.

ii. Drug class review presentation by MagellanRx.

iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.

iv. Presentation of recommendations for PDL inclusion by MagellanRx.

v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

c. **For Possible Action:** Discussion and possible adoption of **Targeted Immunomodulators**

i. Public comment.

ii. Drug class review presentation by MagellanRx.

iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.

iv. Presentation of recommendations for PDL inclusion by MagellanRx.

v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

d. **For Possible Action:** Discussion and possible adoption of **Atypical Antipsychotics Long Acting Injectables**

i. Public comment.

ii. Drug class review presentation by MagellanRx.

iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.

iv. Presentation of recommendations for PDL inclusion by MagellanRx.

v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

5. **Annual Review - Established Drug Classes Being Reviewed Due to the Release of New Generics (Please note: Drug Classes are in bold below.)**

a. **For Possible Action:** Discussion and possible adoption of **Ophthalmic Corticosteroids**

i. Public comment.

ii. Drug class review presentation by MagellanRx.

iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.

iv. Presentation of recommendations for PDL inclusion by MagellanRx.

v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

b. **For Possible Action:** Discussion and possible adoption of **Dipeptidyl Peptidase-4 Inhibitors (DPP-4) and Combinations with Metformin**

i. Public comment.

ii. Drug class review presentation by MagellanRx.

iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.

iv. Presentation of recommendations for PDL inclusion by MagellanRx.

v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

6. Annual Review - New Drug Classes for Proposed Addition (Please note: Drug Classes are in bold below.)

a. **For Possible Action:** Discussion and possible adoption of **Immune Globulins**

- i. Public comment.
- ii. Drug class review presentation by MagellanRx.
- iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
- iv. Presentation of recommendations for PDL inclusion by MagellanRx.
- v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

6.7. Annual Review - Established Drug Classes with Proposed Changes (Please note: Drug Classes are in bold below.)

a. **For Possible Action:** Discussion and possible adoption of **Movement Disorders**

- i. Public comment.
- ii. Drug class review presentation by MagellanRx.
- iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
- iv. Presentation of recommendations for PDL inclusion by MagellanRx.
- v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

b. **For Possible Action:** Discussion and possible adoption of **Topical Retinoids**

- i. Public comment.
- ii. Drug class review presentation by MagellanRx.
- iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
- iv. Presentation of recommendations for PDL inclusion by MagellanRx.
- v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

c. **For Possible Action:** Discussion and possible adoption of **Opioid Agonists**

- i. Public comment.
- ii. Drug class review presentation by MagellanRx.
- iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
- iv. Presentation of recommendations for PDL inclusion by MagellanRx.
- v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

d. **For Possible Action:** Discussion and possible adoption of **Mixed Acting Opioid Analgesics**

- i. Public comment.
- ii. Drug class review presentation by MagellanRx.
- iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
- iv. Presentation of recommendations for PDL inclusion by MagellanRx.
- v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

- e. **For Possible Action:** Discussion and possible adoption of **Leukotriene Receptor Antagonists**
 - i. Public comment.
 - ii. Drug class review presentation by MagellanRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by MagellanRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

- f. **For Possible Action:** Discussion and possible adoption of **Vasodilators – Oral**
 - i. Public comment.
 - ii. Drug class review presentation by MagellanRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by MagellanRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

- g. **For Possible Action:** Discussion and possible adoption of **Vasodilators – Inhaled**
 - i. Public comment.
 - ii. Drug class review presentation by MagellanRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by MagellanRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

- g-h. **For Possible Action:** Discussion and possible adoption of **Monoclonal Antibodies for Respiratory Conditions**
 - i. Public comment.
 - ii. Drug class review presentation by MagellanRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by MagellanRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

7.8. Annual Review - Established Drug Classes without Proposed Changes

- a. Public Comment
- b. **For Possible Action:** Discussion and possible adoption of established drug classes within the Preferred Drug List (PDL)* as presented by MagellanRx and the Division of Health Care Financing and Policy without changes.
 - i. Analgesics - Miscellaneous Analgesics, Neuropathic Pain/Fibromyalgia; Opiate Agonists - Abuse Deterrent; Non-Steroidal Anti - Inflammatory Drugs – Oral
 - ii. Antihistamines - H1 blockers- non-Sedating
 - iii. Anti-infective Agents - Aminoglycosides, Inhaled Aminoglycosides; Antivirals, Alpha Interferons,

- Anti-hepatitis Agents – Polymerase Inhibitors/Combination Products, Anti-hepatitis Agents – Ribavirin; Anti-herpetic Agents, Influenza Agents; Cephalosporins, Second-Generation Cephalosporins, Third-Generation Cephalosporins; Macrolides; Quinolones, Quinolones – 2nd Generation, Quinolones – 3rd Generation
- iv. Autonomic Agents – Sympathomimetics, Self-Injectable Epinephrine
 - v. Biologic Response Modifiers - Immunomodulators, Colony Stimulating Factors; Multiple Sclerosis Agents, Injectable, Oral, Specific Symptomatic Treatment
 - vi. Cardiovascular Agents - Antihypertensive Agents, Angiotensin II Receptor Antagonists, Angiotension Converting Enzyme Inhibitor, Beta-Blockers, Calcium-Channel Blockers, ~~Vasodilators – Inhaled~~; Antilipemics, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, HMG-CoA Reductase Inhibitors (Statins), Niacin Agents, Omega-3 Fatty Acids, PCSK9 Inhibitors; Miscellaneous Heart Failure Agents
 - vii. Dermatological Agents - Antipsoriatic Agents; Topical Analgesics; Topical Anti-infectives, Acne Agents: Topical, Benzoyl Peroxide, Antibiotics, and Combination Products, Impetigo Agents: Topical, Topical Antivirals, Topical Scabicides; Topical Anti-inflammatory Agents, Immunomodulators: Atopic Dermatitis
 - viii. Electrolytes and Renal Agents - Phosphate Binding Agents; Potassium Removing Agents
 - ix. Gastrointestinal Agents - Antiemetics, Pregnancy-induced Nausea and Vomiting Treatment, Serotonin Receptor Antagonists/Combo; Antiulcer Agents, H2 Blockers, Proton Pump Inhibitors (PPIs); Functional Gastrointestinal Disorder Drugs; Gastrointestinal Anti-inflammatory Agents; Gastrointestinal Enzymes
 - x. Genitourinary Agents - Benign Prostatic Hyperplasia Agents, 5-Alpha Reductase Inhibitors, Alpha-Blockers; Bladder Antispasmodics
 - xi. Hematological Agents - Anticoagulants, Oral, Injectable; Erythropoiesis-Stimulating Agents; Platelet Inhibitors
 - xii. Hormones and Hormone Modifiers - Androgens; Antidiabetic Agents, Alpha Glucosidase Inhibitors/Amylin analogs/Mics, Biguanides, Incretin Mimetics and Combinations, Meglitinides, Sulfonylureas, Thiazolidinediones and Combinations; Anti-Hypoglycemic Agents; Insulins, Rapid-Acting Insulins, Short-Intermediate Acting Insulins, Long-Acting Insulins, Pre-Mixed Insulin Combinations; Progestins for Cachexia
 - xiii. Musculoskeletal Agents – Antigout Agents; Bone Resorption Inhibitors, Bisphosphonates, Nasal Calcitonins; Restless Leg Syndrome Agents; Skeletal Muscle Relaxants
 - xiv. Neurological Agents - Alzheimer’s Agents, Cholinesterase Inhibitors, NMDA Receptor Antagonists; Anticonvulsants, Barbiturates, Benzodiazepines, Hydantoins; Anti-Migraine Agents, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists, Serotonin-Receptor Agonists (Triptans); Antiparkinsonian Agents, Dopamine Precursors, Non-Ergot Dopamine Agonists
 - xv. Ophthalmic Agents- Antiglaucoma Agents; Ophthalmic Antihistamines; Ophthalmic Anti-infectives, Ophthalmic Macrolides, Ophthalmic Quinolones; Ophthalmic Anti-infective/Anti-inflammatory Combinations; Ophthalmic Anti-inflammatory agents, Ophthalmic Nonsteroidal Anti-inflammatory Drugs (NSAIDs); Ophthalmics for Dry Eye Disease
 - xvi. Otic Agents - Otic Anti-infectives, Otic Quinolones
 - xvii. Psychotropic Agents- ADHD; Antidepressants, Other; Selective Serotonin Reuptake Inhibitors (SSRIs); Antipsychotics, Atypical Antipsychotics - Oral/Topical; Anxiolytics, Sedatives and Hypnotics; Psychostimulants, Narcolepsy Agents
 - xviii. Respiratory Agents- Nasal Antihistamines; Nasal Corticosteroids, Phosphodiesterase Type 4 Inhibitors; Long-Acting/Maintenance Therapy, Inhaled Glucocorticoids, Glucocorticoids/Long-Acting Beta-2 Adrenergic (LABA) Combination Products, Long-Acting Beta Adrenergics (LABAs), Anticholinergics and Combination Products; Short-Acting/Rescue Therapy, Short-Acting Beta Adrenergics (SABAs), Ipratropium and Combinations
 - xix. Toxicology Agents- Antidotes, Opiate Antagonists; Substance Abuse Agents

xx. Appendix A - Sickle Cell Disease; HIV Prevention

*PDL link: <https://nevadamedicaid.magellanrx.com/provider/documents>

8.9. Annual Review NMAP- New Drug Classes for Proposed Addition

- a. **For Possible Action:** Discussion and possible adoption of **Substance Use Disorder Medications**
- i. Public comment
 - ii. Presentation of recommendations for NMAP formulary inclusion by MagellanRx
 - iii. Discussion by Board and action by Board for approval of drugs for inclusion on formulary

9.10. Annual Review NMAP- Established Drug Classes without Proposed Changes

- a. Public Comment
- b. **For Possible Action:** Discussion and possible adoption of NMAP formulary* as presented by MagellanRx and Division of Public and Behavioral Health without changes.
- i. Antiretrovirals - entry inhibitors; integrase inhibitors; nucleoside & nucleotide reverse transcriptase inhibitors (nrtis); non-nucleoside reverse transcriptase inhibitors (nnrtis); integrase inhibitor/nrti combinations; nnrti/nrti combinations; protease inhibitor (pi)/nrti combinations; cyp3a inhibitors; protease inhibitors (pi); cyp3a4 inhibitor/protease inhibitor combinations; integrase inhibitor/nnrti combinations; cd4-directed post attachment inhibitors; gp 120 directed attachment inhibitors
 - ii. Non-narcotic analgesic (pain relief) medications
 - iii. Antibiotics medications
 - iv. Anticoagulant medications
 - v. Anticonvulsant medications
 - vi. Antidepressant/antipsychotic/hypnotic (sleep aid) medications
 - vii. Antidiarrheal medications
 - viii. Antiemetic (anti-nausea) medications
 - ix. Antifungal medications
 - x. Antihistamine (anti-allergy) medications
 - xi. Antihypertensive (anti-high blood pressure) medications
 - xii. Antivirals
 - xiii. Antivirals-hepatitis
 - xiv. Antivirals-direct acting antivirals (hepatitis c treatment)
 - xv. Gastrointestinal medications
 - xvi. Hematopoietic medications
 - xvii. Hormone replacement therapy medications- androgens; estrogens/estrogenic agents; growth hormone releasing hormone agents; progestins
 - xviii. Hypoglycemic (high blood sugar) medications
 - xix. Inhalers: asthma prevention, bronchodilators; nasal steroids; oral steroids
 - xx. Lipid lowering (anti-cholesterol) medications
 - xxi. Osteoporosis (bone) medications
 - xxii. Pancreatic enzyme medications
 - xxiii. PCP prophylaxis medications
 - xxiv. Topical medications
- *Please see the following:

Generic: [NMAP Formulary \(Alphabetical by Generic\) \(endhivnevada.org\)](http://endhivnevada.org)

Drug Class: [NMAP Formulary by Class \(endhivnevada.org\)](http://endhivnevada.org)

Alpha Brand: [NMPA Formulary \(Alphabetical by Brand Name Drug\) \(endhivnevada.org\)](http://endhivnevada.org)

11. MagellanRx Reports: New Drugs to Market and New Line Extensions

12. Closing Discussion

- a. Public comments on any subject.
(No action may be taken upon a matter raised under the public comment period unless the matter itself has been specifically included on an agenda as an action item. Comments will be limited to three minutes per person. Persons making comments will be asked to begin by stating their name for the record and to spell their last name and provide the secretary with written comments.)
- b. **For Possible Action:** Date and location of the next meeting.
- c. Adjournment.

PLEASE NOTE: Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comments may be limited to three minutes.

This notice and agenda have been posted online at <http://dhcftp.nv.gov> and <http://notice.nv.gov> as well as Carson City, Las Vegas, and Reno central offices for the Division of Health Care Financing and Policy. Email notice has been made to such individuals as have requested notice of meetings (to request notifications please contact rxinfo@dhcftp.nv.gov, or at 1100 East William Street, Suite 101, Carson City, Nevada 89701).

If you require a physical copy of supporting material for the public meeting, please contact rxinfo@dhcftp.nv.gov, or at 1100 East William Street, Suite 101, Carson City, Nevada 89701). Limited copies of materials will also be available on site at the meeting's physical location. Supporting material will also be posted online at <http://dhcftp.nv.gov> and <https://nevadamedicaid.magellanrx.com/provider/drug-utilization-review>

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.

Note: We are pleased to make reasonable accommodations for members of the public with a disability and wish to participate. If accommodated arrangements are necessary, notify the Division of Health Care Financing and Policy as soon as possible and at least ten days in advance of the meeting, by e-mail at rxinfo@dhcftp.nv.gov in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701.

Full Microsoft Teams Link:

<https://events.teams.microsoft.com/event/a20be3a4-483a-405d-84b7-ecf51d65d952@a9df4fcb-7f39-49f4-9d70-1ee81b27a772>